1 / 17

Michael H. Ossipov, Ph.D. Department of Pharmacology

0. Neuromuscular Blocking Drugs. Michael H. Ossipov, Ph.D. Department of Pharmacology. 0. Neuromuscular blocking drugs. Extract of vines (Strychnos toxifera; also Chondrodendron species) Used by indegenous peoples of Amazon basin in poison arrows (not orally active, so food is safe to eat)

gada
Download Presentation

Michael H. Ossipov, Ph.D. Department of Pharmacology

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript


  1. 0 Neuromuscular Blocking Drugs Michael H. Ossipov, Ph.D. Department of Pharmacology

  2. 0 Neuromuscular blocking drugs • Extract of vines (Strychnos toxifera; also Chondrodendron species) • Used by indegenous peoples of Amazon basin in poison arrows (not orally active, so food is safe to eat) • Brought to Europe by Sir Walter Raleigh, others • Curare-type drugs: Tubocurare (bamboo tubes), Gourd curare, Pot curare • Brody (1811) showed curare is not lethal is animal is ventilated • Harley (1850) used curare for tetanus and strychnine poisoning • Harold King (1935) isolates d-tubocurarine from a museum sample – determines structure.

  3. 0 Neuromuscular blocking drugs • Block synaptic transmission at the neuromuscular junction • Affect synaptic transmission only at skeletal muscle • Does not affect nerve transmission, action potential generation • Act at nicotinic acetylcholine receptor NII

  4. 0 Neuromuscular blocking drugs (CH3)3N+-(CH2)6-N+(CH3)3 Hexamethonium (ganglionic) (CH3)3N+-(CH2)10-N+(CH3)3 Decamethonium (motor endplate)

  5. 0 Neuromuscular blocking drugs • Acetylcholine is released from motor neurons in discrete quanta • Causes “all-or-none” rapid opening of Na+/K+ channels (duration 1 msec) • Development of miniature end-plate potentials (mEPP) • Summate to form EPP and muscle action potential – results in muscle contraction • ACh is rapidly hydrolyzed by acetylcholinesterase; no rebinding to receptor occurs unless AChE inhibitor is present

  6. 0 Non-depolarizing Neuromuscular blocking drugs • Competetive antagonist of the nicotinic 2 receptor • Blocks ACh from acting at motor end-plate • Reduction to 70% of initial EPP needed to prevent muscle action potential • Muscle is insensitive to added Ach, but reactive to K+ or electrical current • AChE inhibitors increase presence of ACh, shifting equilibrium to favor displacing the antagonist from motor end-plate

  7. 0 Nondepolarizing drugs: Metabolism • Important in patients with impaired organ clearance or plasmacholinesterase deficiency • Hepatic metabolism and renal excretion (most common) • Atracurium, cis-atracurium:nonenzymatic (Hoffman elimination) • Mivacurium: plasma cholinesterase

  8. 0 Depolarizing Neuromuscular blocking drugs • Succinylcholine, decamethonium • Bind to motor end-plate and cause immediate and persistent depolarization • Initial contraction, fasciculations • Muscle is then in a depolarized, refractory state • Desensitization of Ach receptors • Insensitive to K+, electrical stimulation • Paralyzes skeletal more than respiratory muscles

  9. 0 Succinlycholine: Pharmacokinetics • Fast onset (1 min) • Short duration of action (2 to 3 min) • Rapidly hydrolyzed by plasma cholinesterase

  10. 0 Succinlycholine: Clinical uses • Tracheal intubation • Indicated when rapid onset is desired (patient with a full stomach) • Indicated when a short duration is desired (potentially difficult airway)

  11. 0 Succinylcholine: Side effects • Prolonged neuromuscular blockade • In patients lacking pseudocholinesterase • Treat by maintaining ventilation until it wears off hours later

  12. 0 Succinylcholine: Phase II block • Prolonged exposure to succinlycholine • Features of nondepolarizing blockade • May take several hours to resolve • May occur in patients unable to metabolize succinylcholine (cholinesterase defects, inhibitors) • Harmless if recognized

  13. 0 Acetylcholinesterase inhibitors • Acetylcholinesterase inhibitors have muscarinic effects • Bronchospasm • Urination • Intestinal cramping • Bradycardia • Prevented by muscarinic blocking agent

  14. 0 Selection of muscle relexant: • Onset and duration • Route of metabolism and elimination

  15. 0 Monitoring NM blockade • Stimulate nerve • Measure motor response (twitch) • Depolarizing neuromuscular blocker • Strength of twitch • Nondepolarizing neuromuscular blocker • Strength of twitch • Decrease in strength of twitch with repeated stimulation

  16. 0

More Related